Andres Metspalu

Andres Metspalu

Auto-generated profile, based on publicly available information

Andres Metspalu

Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2010 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
TCThe ENGAGE Consortium
The ENGAGE Consortium
TTThorgeir E Thorgeirsson
Thorgeir E Thorgeirsson
DGDaniel F Gudbjartsson
Daniel F Gudbjartsson
ISIda Surakka
Ida Surakka
JVJacqueline M Vink
Jacqueline M Vink
KSKari Stefansson
Kari Stefansson

1 February 2014 in BMC Endocrine Disorders
Verified
Journal Article
Open access
PDF file
JVJana V van Vliet-Ostaptchouk
Jana V van Vliet-Ostaptchouk
MNMarja-Liisa Nuotio
Marja-Liisa Nuotio
SSSandra N Slagter
Sandra N Slagter
DDDany Doiron
Dany Doiron
KFKrista Fischer
Krista Fischer
BWBruce H.R. Wolffenbuttel
Bruce H.R. Wolffenbuttel
Not all obese subjects have an adverse metabolic profile predisposing them to developing type 2 diabetes or cardiovascular disease. The BioSHaRE-EU Healthy Obese Project aims to gain insights into the consequences of (healthy) obesity using data on risk factors and phenotypes across several large-scale cohort studies. Aim of this study was to describe the prevalence of obesity, metabolic syndrome (MetS) and metabolically healthy obesity (MHO) in ten participating studies. Ten different cohorts in seven countries were combined, using data transformed into a harmonized format. All participants were of European origin, with age 18–80 years. They had participated in a clinical examination for anthropometric and blood pressure measurements. Blood samples had been drawn for analysis of lipids and glucose. Presence of MetS was assessed in those with obesity (BMI ≥ 30 kg/m2) based on the 2001 NCEP ATP III criteria, as well as an adapted set of less strict criteria. MHO was defined as obesity, having none of the MetS components, and no previous diagnosis of cardiovascular disease. Data for 163,517 individuals were available; 17% were obese (11,465 men and 16,612 women). The prevalence of obesity varied from 11.6% in the Italian CHRIS cohort to 26.3% in the German KORA cohort. The age-standardized percentage of obese subjects with MetS ranged in women from 24% in CHRIS to 65% in the Finnish Health2000 cohort, and in men from 43% in CHRIS to 78% in the Finnish DILGOM cohort, with elevated blood pressure the most frequently occurring factor contributing to the prevalence of the metabolic syndrome. The age-standardized prevalence of MHO varied in women from 7% in Health2000 to 28% in NCDS, and in men from 2% in DILGOM to 19% in CHRIS. MHO was more prevalent in women than in men, and decreased with age in both sexes. Through a rigorous harmonization process, the BioSHaRE-EU consortium was able to compare key characteristics defining the metabolically healthy obese phenotype across ten cohort studies. There is considerable variability in the prevalence of healthy obesity across the different European populations studied, even when unified criteria were used to classify this phenotype.

6 September 2021 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
JMJosine L. Min
Josine L. Min
GHGibran Hemani
Gibran Hemani
EHEilis Hannon
Eilis Hannon
KDKoen F. Dekkers
Koen F. Dekkers
JCJuan Castillo-Fernandez
Juan Castillo-Fernandez
CRCaroline L. Relton
Caroline L. Relton

11 February 2014 in International Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
LLLiis Leitsalu
Liis Leitsalu
THToomas Haller
Toomas Haller
TETõnu Esko
Tõnu Esko
MTMari-Liis Tammesoo
Mari-Liis Tammesoo
HAHelene Alavere
Helene Alavere
AMAndres Metspalu
Andres Metspalu
The Estonian Biobank cohort is a volunteer-based sample of the Estonian resident adult population (aged ≥18 years). The current number of participants—close to 52000-—represents a large proportion, 5%, of the Estonian adult population, making it ideally suited to population-based studies. General practitioners (GPs) and medical personnel in the special recruitment offices have recruited participants throughout the country. At baseline, the GPs performed a standardized health examination of the participants, who also donated blood samples for DNA, white blood cells and plasma tests and filled out a 16-module questionnaire on health-related topics such as lifestyle, diet and clinical diagnoses described in WHO ICD-10. A significant part of the cohort has whole genome sequencing (100), genome-wide single nucleotide polymorphism (SNP) array data (20 000) and/or NMR metabolome data (11 000) available (http://www.geenivaramu.ee/for-scientists/data-release/). The data are continuously updated through periodical linking to national electronic databases and registries. A part of the cohort has been re-contacted for follow-up purposes and resampling, and targeted invitations are possible for specific purposes, for example people with a specific diagnosis. The Estonian Genome Center of the University of Tartu is actively collaborating with many universities, research institutes and consortia and encourages fellow scientists worldwide to co-initiate new academic or industrial joint projects with us.

2 October 2019 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
GSGerman Chronic Kidney Disease Study
German Chronic Kidney Disease Study
ATAdrienne Tin
Adrienne Tin
LSLifelines Cohort Study
Lifelines Cohort Study
VPV. A. Million Veteran Program
V. A. Million Veteran Program
JMJonathan Marten
Jonathan Marten
AKAnna Köttgen
Anna Köttgen

18 June 2020 in Nature Reviews Clinical Oncology
Verified
Journal Article
Open access
PDF file
NPNora Pashayan
Nora Pashayan
AAAntonis C. Antoniou
Antonis C. Antoniou
UIUrska Ivanus
Urska Ivanus
LELaura J. Esserman
Laura J. Esserman
DEDouglas F. Easton
Douglas F. Easton
MWMartin Widschwendter
Martin Widschwendter
The European Collaborative on Personalized Early Detection and Prevention of Breast Cancer (ENVISION) brings together several international research consortia working on different aspects of the personalized early detection and prevention of breast cancer. In a consensus conference held in 2019, the members of this network identified research areas requiring development to enable evidence-based personalized interventions that might improve the benefits and reduce the harms of existing breast cancer screening and prevention programmes. The priority areas identified were: 1) breast cancer subtype-specific risk assessment tools applicable to women of all ancestries; 2) intermediate surrogate markers of response to preventive measures; 3) novel non-surgical preventive measures to reduce the incidence of breast cancer of poor prognosis; and 4) hybrid effectiveness–implementation research combined with modelling studies to evaluate the long-term population outcomes of risk-based early detection strategies. The implementation of such programmes would require health-care systems to be open to learning and adapting, the engagement of a diverse range of stakeholders and tailoring to societal norms and values, while also addressing the ethical and legal issues. In this Consensus Statement, we discuss the current state of breast cancer risk prediction, risk-stratified prevention and early detection strategies, and their implementation. Throughout, we highlight priorities for advancing each of these areas.